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Abstract
Background: Neonatal jaundice is a common finding in newborns in Asia, including Indonesia. In some cases, the
serum total bilirubin levels exceeds the 95th percentile for hours of life (neonatal hyperbilirubinemia). Severe
neonatal hyperbilirubinemia (NH) could lead to kernicterus and neonatal death. Glucose-6-Phosphage Dehydrogenase
(G6PD) genetic variations and deficiency have been reported in several studies to be associated with NH. This study
aimed to analyze the G6PD genetic variations and its activity in neonates with and without hyperbilirubinemia in
the Deutromalay Indonesian population.
Methods: Deoxyribose Nucleic Acid (DNA) was isolated from peripheral blood of 116 and 115 healthy term
neonates with and without hyperbilirubinemia. All infants underwent the following laboratory examinations: routine
hematologic evaluation, Coombs test, G6PD activity measurement using the Randox kit method, and serum total
bilirubin level. All exons of the G6PD gene were targeted for deep sequencing using MiSeq (Illumina). An
association study of G6PD polymorphisms with NH was performed using PLINK.
Results: The prevalence of G6PD deficiency in neonates with and without hyperbilirubinemia in Indonesian
Deutromalay population were 1.72% (95% Confidence Interval (CI): 0.6–4.1%) and 1.74% (95% CI: 0.7–4.1%),
respectively. The most common G6PD polymorphisms, i.e. rs1050757/c.* + 357A > G, rs2230037/c.1311C > T, and
rs2071429/c.1365-13 T/IVS11, were identified. However, none of those polymorphisms and their haplotype were
associated with NH (p > 0.05, Odds Ratio (OR) ~1.00). The prevalence of G6PD mutations in neonates with and
without hyperbilirubinemia were 6.8% (95% CI: 2.3–11.5%) and 6.9% (95% CI: 2.3–11.6%), respectively. The most
frequently identified G6PD mutation was the Viangchan variant (p.V291 M), which was followed by the Canton
(p.R459L) and Vanua Lava (p.L128P) variants. Two novel mutations were identified both in case (p.V369A, p.I167F)
and control (p.L474=, p.I36T) groups.
Conclusion: The prevalence of G6PD deficiency is low in neonates with or without hyperbilirubinemia in
Deutromalay Indonesian population. The majority of G6PD mutations identified among Indonesian Deutromalay
population in this study are Viangchan, Canton and Vanua Lava variants.
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Background
Glucose-6-phosphate-dehydrogenase (G6PD) is a
“housekeeping” gene encoding the G6PD enzyme which
catalyzes glucose-6-phoshpate conversion to 6-
phosphogluconolactone in the pentose monophosphate
pathways in all cells [1, 2]. This enzyme is also import-
ant for maintaining red blood cells (RBCs) and protect-
ing them from damages or premature destruction
caused by oxidative stress through the maintenance of
Nicotinamide Adenine Dinucleotide (NADP) and Nico-
tinamide Adenine Dinucleotide Phosphate Hydrogen
(NADPH) levels [1, 2]. Although G6PD deficiency af-
fects all cells in the body, the most affected cells are
RBCs because these cells have no alternative pathways
to produce NADPH [1]. The G6PD gene, 18 k base (kb)
long and is located on chromosome Xq28, consists of
13 exons and 12 introns. The complete coding sequence
is 1548 base pair (bp) long and encodes 514 amino acids
[1, 3, 4]. Mutations throughout the G6PD gene lead to a
deficiency in protein functions. Based on their biochemical
and physicochemical characteristics, over 400 variants of
G6PD have been reported. However, based on the type of
mutations, those protein variants resulted from only ~140
different mutations [3–5]. Glucose-6-phosphate-dehydro-
genase deficiency is the most common pentose monopho-
sphate pathway enzyme deficiency that has been reported
to affect 400 million people globally with the highest inci-
dence in African, Mediterranean, and South Asian popula-
tions [3, 6].
G6PD deficiency is inherited in an X-linked fashion,
being fully expressed in hemizygous males and homozy-
gous females. In most cases, G6PD deficiency is asymp-
tomatic. However, in some cases, acute hemolysis could
be induced by oxidative stress, such as in hypoxia, bac-
terial or viral infection, or exposure to certain foods
(e.g., Fava beans), chemicals, or drugs (e.g., quinolones/
antimalarials) [7]. G6PD deficiency can also cause life-
threatening hemolytic anemia during childhood with se-
vere neonatal hyperbilirubinemia (NH) as the most fatal
consequences of G6PD deficiency that can lead to
chronic bilirubin encephalopathy (kernicterus) and spas-
tic cerebral palsy [7].
G6PD deficiency and genetic variations (polymorph-
ism and mutations) have been reported to be associ-
ated with hemoglobinuria or NH in several
populations [6, 8]. Neonatal hyperbilirubinemia is
quite common in Indonesia; however, it is not yet
known whether G6PD genetic variants (polymor-
phisms and mutations) and deficiency are the risk fac-
tors for NH in the Indonesian population. Here we
present a complete mutational and polymorphism
analysis of G6PD and its activity in newborns with and
without hyperbilirubinemia in Indonesian Deutroma-
lay population.
Methods
Subjects
The subjects were healthy term neonates with hyperbi-
lirubinemia (NH), defined as total serum bilirubin (TSB)
above the 95th percentile for age in hours based on Bhu-
tani’s nomogram. Neonates with TSB below the 40th
percentile for age in hours based on Bhutani’s nomo-
gram were included in this study as the control group.
All neonates in both groups were single births. Neonates
born to mothers with diabetes and those with neonatal
sepsis, cephalohematoma, ABO or Rhesus blood group
incompatibility with their mothers, or other congenital
diseases which would affect the level of bilirubin in the
serum were excluded. Two hundreds Seventy Six healthy
term neonates from the Indonesian Deutromalay popu-
lation were recruited consecutively from 5 hospitals in
Sumatra and western part of Java islands. In total, only
116 and 115 neonates met the inclusion criteria for case
and control groups, respectively, were included in this
study. Written informed consent was obtained from par-
ents, and the study was approved by the Ethics Commit-
tee of the Faculty of Medicine, Universitas Padjadjaran,
Bandung, Indonesia. The characteristics of neonates and
their mothers are presented in Table 1.
Measurement of G6PD activity
Red blood cell (RBC) G6PD activity assays was performed
in 231 neonates using a G6PD assay kit from Randox La-
boratory LTD (PD410, United Kingdom) in triplicate for
each sample. All G6PD activity assays were performed
within 24 h of sample collection. Results of G6PD meas-
urement were calculated in mUnits (U)/109 erythrocytes.
The G6PD enzyme activity was then converted into Units
per g Hemoglobin (U/g Hb). The median value of G6PD
activity of male in control group (13.10 U/g Hb) was used
as the standard for 100% enzyme activity in this study.
The results of G6PD activities were classified as deficiency
when the enzyme activity was <30% and was considered
as intermediate and normal when the activity was 30–80%
and > 80%, respectively.
DNA isolation
Genomic DNA was isolated from 300 μl of peripheral
blood leukocytes using a DNA isolation kit (Roche Life
Sciences) according to the manufacturer’s protocol. The
DNA concentration was measured using a Nano-
Drop™2000 (Thermo Fisher Scientific).
Deep-targeted next-generation sequencing (NGS) and
data analysis
The G6PD gene was enriched with the TruSeq Custom
Amplicon assay (Illumina, San Diego, USA) and oligos
were designed using Design Studio (Illumina, San Diego,
USA). Amplicons covered all exons and exon-intron
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boundaries with 10 bp on each end. The amplicons were
sequenced using paired-end sequencing of 2 × 250 bps
on a MiSeq (Illumina, San Diego, CA, USA). Data pro-
cessing was performed as described in the previous study
[9]. Variants that were not present in the database of
Single Nucleotide Polymorphism 138 (dbSNP138) or
had minor allele frequencies (MAFs) < 0.01 in the 1000
Genomes Project database were categorized as muta-
tions (rare variants) and variants that were present in
the dbSNP138 database with MAFs ≥0.01 in the 1000
Genomes Project database were categorized as polymor-
phisms (common variants).
Association analysis of identified polymorphisms
Association analysis of polymorphisms with NH was
performed using PLINK, an open-source whole-genome-
association analysis tool set which can be used to per-
form a range of basic to large-scale association analyses
of genotype/phenotype data [10]. Polymorphisms that
were monomorphic had MAFs less than 0.05 or were
missing in 95% all subjects were excluded from the asso-
ciation test. The false discovery rate was used for mul-
tiple testing to correct P values [11].
Validation of G6PD mutations
Mutations identified by targeted deep sequencing using
Next-Generation Sequencing (NGS) method on MiSeq
(Illumina, San Diego, CA, USA) were validated using
polymerase chain reaction (PCR) and Sanger sequencing.
Validation was only performed when DNA was still
available. The primers used to amplify target exons of
G6PD were designed using Primer3 V.0.4.0 software
(http://bioinfo.ut.ee/primer3-0.4.0/) and the primers se-
quences were presented in Additional file 1: Table S1.
Polymerase Chain Reaction (PCR) and Sanger sequen-
cing to validate the mutations identified by MiSeq were
performed as described in our previous study [9].
In silico analysis
The pathogenicity of identified G6PD mutations was pre-
dicted using Polymorphism Phenotyping V2 (PolyPhen-2)
(http://genetics.bwh.harvard.edu/pph2/) and Mutation
Taster® (http://www.mutationtaster.org/) program.
Results
Subjects characteristics
Although the difference was not significant, there were
more boys (52.2–52.6%) than girls (47.4–47.8%) in both
case and control groups. The mean birth weight was
3125 ± 345 g in the case group and 3138 ± 371 g in the
control group. The results of ABO and Rhesus blood
grouping incompatibility between mothers and neonates
were negative in all samples (Table 1). There was no sig-
nificant difference in feeding methods, maternal age, or
parity between case and control groups. The majority of
mothers in both groups had Cesarean delivery (57–87%)
(Table 1). The histogram of total serum bilirubin (TSB)
level distribution in case and control groups is presented
in Fig. 1.
The prevalence of G6PD deficiency
The prevalence of G6PD deficiency in case (2/116) and
control (2/115) groups were 1.72% (95% CI: 0.6–4.1%)
and 1.74% (95% CI: 0.7–4.1%), respectively.
G6PD polymorphisms and association study
Nine G6PD polymorphisms were identified in cases and
controls but only three of them (rs1050757/c.* + 357A >
G, rs2230037/c.1311C > T, and rs2071429/c.1365-13 T/
IVS11) had MAFs >0.05 in this population. Therefore,
Table 1 Characteristic of Neonates and Mothers in Case and
Control Groups
Characteristic Cases Controls p-value*
(N = 116) % (N = 115) %
Neonates
Birth Weight (gram) 0.772
Average (SD) 3125 (345.6) – 3138 (371.2) –
Range 2500–4300 – 2500–4250 –
Feeding 0.483
Breast milk 94 81.0 98 85.3
Formula 0 0 0 0
Mix of both 22 19.0 17 14.7
Sibling with Jaundice 0.319
Yes 26 22.4 19 16.4
No 90 77.6 96 80.6
ABO Blood Group 18 15.5 9 7.75 0.065
Coombs Test Results
Negative 116 115 –
Positive 0 0
Mothers
Age (Years)
Average (SD) 30 (6.1) – 30.9 (5.8) – 0.208
Parity
1 54 46.6 41 35.7 0.063
Delivery method
Cesarean delivery 57 49.1 87 75.7 < 0.001
Normal 53 45.7 28 24.3
Vacuum 3 2.6 0 0
Forceps 3 2.6 0 0
Consanguinity –
No 116 100 115 100
*) Chi–square. except Birth weight
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only those three polymorphisms and combinations of
these variants (haplotypes) can be analyzed using PLINK.
None of those polymorphisms and haplotypes were asso-
ciated with NH in this population, as the p-value was
>0.05 and the OR was ~1.00 (Table 2). In total, there
were 4 G6PD-deficient subjects in case and control
groups, but only 2 (50%) were identified with a combin-
ation of these three polymorphisms (Table 3).
G6PD mutations and in silico analysis
The frequencies of mutations in the case and control
groups were not significantly different. Eight G6PD mu-
tations were identified in each group, hence the G6PD
mutation frequencies in cases (8/116) and controls (8/
115) were 6.8% (95% CI:2.3–11.5%) and 6.9% (95% CI:
2.3–11.6%), respectively (Table 3). In total, from those
neonates who carried G6PD mutations, nine different
mutations identified in six and eight neonates from the
case and control groups, respectively (Table 3). Among
those mutations, two novel mutations were identified in
both case and control groups. The two novel mutations
identified in cases were all missense mutations (c.1106
T > C/p.V369A and c.499A > T/p.I167F), whereas in con-
trols, one of them was a silent mutation (c.1422G > A/
p.L474=) and the other was a missense mutation (c.107
T > C/p.I36T). The Viangchan variant (c.871G > A/
p.V291M) was the most frequently identified mutation
in both cases and controls (three neonates in each
group), followed by the Canton variant (c.1376G > T/
p.R459L) and Vanua Lava variant (c.383TA/p.L128P)
Fig. 1 Histogram of Total Serum Bilirubin (TSB) level (μMol/L) distribution in: a) Neonates without hyperbilirubinemia (control group) and b)
Neonates with hyperbilirubinemia (Cases group)
Table 2 Association of G6PD Polymorphisms with NH
No. SNP Location AA Change Coordinate (Hg19) Ref F_A F_U Alt P OR 95% CI q-value
1 rs1050757 Intronic – 153,759,858 C 0.3000 0.2692 T 0.4626 1.163 0.66–2.06 0.6168
2 rs2230037 3UTR – 153,760,654 A 0.2913 0.2735 G 0.6702 1.092 0.62–1.94 0.7468
3 rs2071429 Exon 11 p.Y437= 153,760,508 G 0.2913 0.2778 A 0.7468 1.069 0.60–1.89 0.7468
AA Amino Acid, Alt Alternative, CI Confidence of Interval, F_A Frequency Alt in Cases, F_U Frequency Alt in Controls, Hg19 Human genome version 19, OR Odds
Ratio, Ref Reference
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which were identified in one neonate in each group. The
Kaiping variant (c.1388G > A/p.R463H) was identified
only in one case, and the Chatham variant (c.1003G > A/
p.A335T) was identified only in one control (Table 3).
The mutations identified in this population differ from
those in previous studies in eastern Indonesian popula-
tion, in which the predominant variant identified was
the Vanua Lava variant [12, 13]. Among 4 G6PD-
deficient neonates, two and one subjects in case and
control groups, respectively, were identified as carriers
of G6PD mutations. In the case group, one had the Can-
ton Variant (p.R459L) and the other had a compound
heterozygote with the Viangchan and Vanua Lava
(p.L128P) variants (Table 3). In the control group, one
subject was identified with the Viangchan variant, and
the other did not have either G6PD mutation or poly-
morphism (Table 3). Hence, in this population, 75% (3/
4) of G6PD-deficient neonates were carrying G6PD mu-
tations. To predict the pathogenicity of identified muta-
tions, in silico analysis using Polypen-2 and Mutation
Taster® was performed. Most of the identified mutations,
including the novel ones, were predicted to be disease-
causing or possibly damage-causing variants (Additional
file 1: Table S2). Functional studies on novel mutations
are required to validate the results of in silico analysis.
Validation of G6PD mutations
Among the nine different mutations identified in a total
of 14 neonates (six in case group and eight control
group), only five different mutations (56%) in seven
neonates (50%) were validated by PCR and Sanger
sequencing. Those were the Vanua Lava, Chatham,
Canton, Viangchan, and Kaiping variants (Additional file 1:
Figure S1-S2). Since the DNA samples of the other seven
neonates were no longer available or the quality was signifi-
cantly decreased, the mutations could not be validated by
using Sanger sequencing.
Discussion
The pathophysiology of NH is complex and multifactor-
ial. Studies that have been conducted so far have focused
on the prevalence of NH in G6PD-deficient neonates
and shown that G6PD deficiency is one of the risk fac-
tors for NH in several populations or, at least, that
G6PD-deficient neonates have significantly higher biliru-
bin levels than controls [8, 14]. To date, more than 150
G6PD variants have been identified as causal or risk fac-
tors in G6PD deficiency. Very limited studies have been
performed to analyze G6PD variants (mutations and
polymorphisms) in NH and the association of those vari-
ants with NH. One study has suggested that G6PD-
deficient neonates carrying the c.563C > T G6PD variant
developed jaundice earlier than infants without G6PD
deficiency [15].
The results of this study show that the prevalence of
G6PD deficiency in neonates with hyperbilirubinemia
(NH) in this population (1.72%). This number is lower
than the prevalence of G6PD deficiency in Malaysia
(29.7%), Thailand (22.9%), Egypt (30.2–42%), Pakistan
(17.3%) and India (2.5%) [1, 15–17]. The prevalence of
G6PD deficiency in NH in this population was also
lower than in the population infected by Malaria in east-
ern Indonesian population (Flores [4.4%] and Sumbawa
[3.1–6.7%]) [12, 13]. Furthermore, the prevalence of
G6PD deficiency in case group (1.72%) was similar to
that in control group (1.74%) (Table 3). This shows that
G6PD deficiency is not a major risk factor in the etiology
of NH in this population.
Variant analysis using targeted deep sequencing allows us
to accurately genotype all mutations and polymorphisms in
the exonic regions, their flanking sites, and small parts of
the upstream (3′-UTR) and downstream (5′-UTR) regions
of the gene. Three polymorphisms (rs1050757, rs2230037,
and rs2071429) with MAF >0.05% were identified in cases
and controls. Among those polymorphisms, only one was
located in the coding region: rs2071429 (p.Y437=). This
variant is a silent polymorphism with frequencies of 29%
(0.2913) in NH and 28% (0.2778) in controls (Table 2). As-
sociation analysis using PLINK showed that neither of these
polymorphisms nor their combination (haplotype) were as-
sociated with NH. This study has a limitation in the form
of significantly different cesarean-section rates in case and
control groups (Table 1). This could introduce bias to the
results of this study as the cesarean-section itself has been
reported in the previous studies to be associated with
hyperbilirubinemia [18, 19].
In total, there were 6 and 8 neonates from the case
and control groups, respectively, were identified as car-
riers of G6PD mutations. However, despite of carrying
G6PD mutations with or without polymorphism, only 2
neonates from each group suffer from G6PD deficiency.
Three of those four G6PD-deficient neonates (75%)
carry G6PD mutations with or without polymorphism
and one of them does not have any G6PD coding muta-
tion or polymorphism. This number is similar to those
identified in Egyptian and Chinese population, where 62
and 78% of G6PD-deficient neonates, respectively, are
identified as carriers of G6PD mutations, but lower than
that in Singaporean (90%) and Pakistani population
(94%) [14, 17, 20, 21]. Previous studies have shown that
some variants or a haplotype in the non-coding region
of G6PD (+357A > G/c.1365-13 T > C/c.1311C > T) were
associated with the lower enzyme activity in individual
without G6PD mutation in the coding region [21]. As in
the deep-targeted sequencing method only small part of
UTRs and intronic regions are included in the analysis,
there is a possibility that we missed in identifying non-
coding mutation in one of G6PD-deficient neonates.
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G6PD deficiency is inherited in X-linked recessive pat-
tern, hence this condition mostly affects male neonates.
It is interesting to note that in this study, one of affected
neonates is female. Her enzyme activity was only 2.63%
of normal G6PD activity. This female neonate (ID-80)
have compound heterozygous of Vianchan and Canton
variants with polymorphism. This showing that gene
dosage affects the severity of the enzyme deficiency.
However, predicting the effect of a G6PD mutation in
females is more complicated than in their male counter-
parts. Although the females have two X chromosomes,
one X chromosome is randomly inactivated during em-
bryogenesis. The total gene expression will depend on
the ratio of the X-inactivated wild-type allele to the mu-
tant allele. The remaining G6PD mutations were identi-
fied in male neonates, and most of them did not suffer
from G6PD deficiency (Table 3).
Of all G6PD mutations identified in this study, the
most common is the Viangchan variant (p.V291M),
followed by the Canton (p.R459L) and Vanua Lava
(p.L128P) variants, which are located in exons 9, 12,
and 5, respectively. The predominant mutational type
identified in this study was different from those in
other ethnic groups in Indonesia. A study in Sumba,
eastern Indonesia, has shown that the predominant
G6PD mutation identified in this ethnic group is
Vanua Lava [12]. Indonesia is an archipelago country,
with thousands of islands and more than 100 ethnic
groups. It is not surprising that the predominant mu-
tational type is different in each region in Indonesia.
The ancestors of the Deutromalay, who inhabits the
western part of Indonesia, are believed to have come
from northern China who were migrated to Southeast
Asia. Therefore, the variants identified in this ethnic
group are similar to those in China, Thailand, and
other Southeast Asian countries.
Conclusion
The prevalence of G6PD deficiency is low in neonates
with or without hyperbilirubinemia in Deutromalay
Indonesian population. The G6PD mutations identified
in this population are mostly similar to those identified
in other South East Asian population.
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